Australia
Austria
Belgium
China
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
India
Ireland
Italy
Japan
Kazakhstan
Latvia
Lithuania
Malaysia
Netherlands
Norway
Poland
Singapore
Slovenia
Spain
Sweden
Switzerland
Thailand
UK
Ukraine
We translate world-class science into life-changing therapies
Discover moreDiscover our science and innovation
Explore our news and stories
All articles
The Veturi research ecosystem led by Orion: Personalised medicin...
6/15/2026
Science and Partnering
A stable society does not appear out of the blue – Orion and CMI...
5/11/2026
Early diagnosis gives better outcomes – Taking control of asthma...
5/3/2026
Your Health
The patient journey starts with listening: Why the human side of...
4/20/2026
Your Health
Orion’s production processes in Turku, Finland to become carbon ...
4/9/2026
Sustainability
Half-Year Financial Report January-June 2026
Orion published Half-Year Financial Report January-June 2026 on Friday, 17 July 2026.
Read the report
Stock exchange releases
- 7/17/2026 Orion Group Half-Year Financial Report January–June 2026
- 7/17/2026 Orion Corporation’s financial reporting and Annual General Meeting in 2027
- 7/15/2026 45,611 Orion Corporation A shares converted into B shares
- 5/15/2026 105,950 Orion Corporation A shares converted into B shares
Press releases
- 7/3/2026 Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026
- 6/30/2026 Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market
- 6/23/2026 Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission
- 5/30/2026 Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
Sustainability at Orion Pharma
Our operations help to build the well-being of people, animals and society. At the same time, we strive to minimise the impact of our operations on the environment.
Read more
